HRP20140195T1 - Supstituirani derivati triazolopiridazina - Google Patents

Supstituirani derivati triazolopiridazina Download PDF

Info

Publication number
HRP20140195T1
HRP20140195T1 HRP20140195AT HRP20140195T HRP20140195T1 HR P20140195 T1 HRP20140195 T1 HR P20140195T1 HR P20140195A T HRP20140195A T HR P20140195AT HR P20140195 T HRP20140195 T HR P20140195T HR P20140195 T1 HRP20140195 T1 HR P20140195T1
Authority
HR
Croatia
Prior art keywords
substance
composition
deuterium
pharmaceutically acceptable
disease
Prior art date
Application number
HRP20140195AT
Other languages
English (en)
Croatian (hr)
Inventor
Scott Harbeson
Original Assignee
Concert Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc. filed Critical Concert Pharmaceuticals Inc.
Publication of HRP20140195T1 publication Critical patent/HRP20140195T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20140195AT 2008-08-29 2009-08-28 Supstituirani derivati triazolopiridazina HRP20140195T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Publications (1)

Publication Number Publication Date
HRP20140195T1 true HRP20140195T1 (hr) 2014-04-11

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140195AT HRP20140195T1 (hr) 2008-08-29 2009-08-28 Supstituirani derivati triazolopiridazina

Country Status (17)

Country Link
US (4) US8003646B2 (enExample)
EP (2) EP2328414B1 (enExample)
JP (3) JP5183808B2 (enExample)
KR (1) KR20110063479A (enExample)
CN (2) CN102176826B (enExample)
AU (1) AU2009285533B2 (enExample)
BR (1) BRPI0912928A2 (enExample)
CA (1) CA2735549A1 (enExample)
DK (1) DK2328414T3 (enExample)
EA (1) EA020071B1 (enExample)
ES (1) ES2451542T3 (enExample)
HR (1) HRP20140195T1 (enExample)
MX (1) MX2011002278A (enExample)
PL (1) PL2328414T3 (enExample)
PT (1) PT2328414E (enExample)
WO (1) WO2010025407A1 (enExample)
ZA (1) ZA201102123B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2451542T3 (es) * 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos
WO2010037194A1 (pt) 2008-10-03 2010-04-08 Instituto Alberto Luiz De Coimbra De Pós Graduação E Pesquisa De Engenharia - Coppe/Ufrj Dispositivo para remoção de fragmentos metálicos e elementos metálicos do interior de canáis radiculares de dentes e processo para remoção dos mesmos
US8501738B2 (en) * 2009-06-23 2013-08-06 Concert Pharmaceuticals, Inc. Substituted triazolo-pyridazine derivatives
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
WO2013104705A1 (de) 2012-01-11 2013-07-18 Bayer Intellectual Property Gmbh Tetrazol-5-yl- und triazol-5-yl-arylverbindungen und ihre verwendung als herbizide
US20150119398A1 (en) * 2012-05-11 2015-04-30 Concert Pharmaceuticals Inc. Form 2 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2013170241A1 (en) * 2012-05-11 2013-11-14 Concert Pharmaceuticals, Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolol[4,3b]pyridazine
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
SG11202109526PA (en) * 2019-03-18 2021-10-28 Neurocycle Therapeutics Inc Use of gabaa receptor modulators for treatment of pain
JP2025513560A (ja) * 2022-04-20 2025-04-24 エングレイル セラピューティクス，インコーポレーテッド Ｇａｂａａ受容体モジュレーター塩、粒子、およびその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) * 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
AU723098B2 (en) 1996-07-25 2000-08-17 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
AU748737B2 (en) * 1998-01-21 2002-06-13 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1149102B1 (en) * 1999-01-27 2004-12-08 MERCK SHARP & DOHME LTD. Triazolo-pyridazine derivatives as ligands for gaba receptors
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP4426461B2 (ja) * 2002-11-28 2010-03-03 ニューロサーチ、アクティーゼルスカブ 鎮静薬または抗不安薬としての効力を有する化合物をスクリーニングする方法
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
JP2010501572A (ja) * 2006-08-22 2010-01-21 コンサート ファーマシューティカルズ インコーポレイテッド ４−アミノキナゾリン誘導体およびその使用方法
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
WO2008122020A1 (en) * 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
ES2451542T3 (es) * 2008-08-29 2014-03-27 Concert Pharmaceuticals Inc. Derivados de triazolo-piridazina sustituidos

Also Published As

Publication number Publication date
JP5183808B2 (ja) 2013-04-17
EP2328414B1 (en) 2013-12-11
DK2328414T3 (en) 2014-03-10
EP2716158A1 (en) 2014-04-09
US20120004236A1 (en) 2012-01-05
JP2013100322A (ja) 2013-05-23
JP2012501346A (ja) 2012-01-19
JP2014058518A (ja) 2014-04-03
WO2010025407A1 (en) 2010-03-04
CN102176826B (zh) 2014-08-20
US20130225590A1 (en) 2013-08-29
CN104098578A (zh) 2014-10-15
EA020071B1 (ru) 2014-08-29
CA2735549A1 (en) 2010-03-04
EP2328414A1 (en) 2011-06-08
US20100056529A1 (en) 2010-03-04
CN102176826A (zh) 2011-09-07
AU2009285533A1 (en) 2010-03-04
MX2011002278A (es) 2011-04-14
JP5373982B2 (ja) 2013-12-18
US8399467B2 (en) 2013-03-19
US8921366B2 (en) 2014-12-30
EA201100409A1 (ru) 2011-10-31
EP2328414A4 (en) 2011-11-16
PL2328414T3 (pl) 2014-05-30
PT2328414E (pt) 2014-03-17
US20150111895A1 (en) 2015-04-23
US8003646B2 (en) 2011-08-23
KR20110063479A (ko) 2011-06-10
BRPI0912928A2 (pt) 2015-08-04
AU2009285533B2 (en) 2014-02-13
ES2451542T3 (es) 2014-03-27
ZA201102123B (en) 2011-12-28
AU2009285533A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
HRP20241197T1 (hr) Makrociklični spojevi i primjene istih
HRP20241540T1 (hr) Pirolotriazinski spojevi koji djeluju kao inhibitor mnk
HRP20110289T1 (hr) Makrociklički inhibitori virusa hepatitisa c
WO2019079607A9 (en) Methods of using ehmt2 inhibitors in treating or preventing blood disorders
ES2630115T3 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9
ES2977656T3 (es) Inhibidores de KDM1A para el tratamiento de enfermedades
HRP20160641T1 (hr) Fuzionirani triciklički spojevi kao inhibitori raf kinaze
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
MX2009007018A (es) Ligandos para formacion de imagen de inervacion cardiaca.
HRP20221018T1 (hr) Liječenje katapleksije
AR063351A1 (es) DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA.
ME02490B (me) Hemijska jedinjenja
ME02321B (me) Antivirusna jedinjenja
HRP20080018T3 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer
HRP20211973T1 (hr) Kinazolini kao inhibitori ionskih kalijskih kanala
HRP20170955T1 (hr) Derivati kinolin-8-sulfonamida s antikancerogenim djelovanjem
WO2017139404A1 (en) Methods of treating cancer
AU2012335981C1 (en) Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
HRP20140409T1 (hr) Derivat imidazola sa strukturom prolinskog prstena
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
HRP20171053T1 (hr) Derivati oksokinazolinil-butanamida
TN2009000483A1 (fr) Derives de 7-alkynyl-1-8-naphthyridones, leur preparation et leur application en therapeutique